USPTO Issues Notice of Allowance to Epigentek for its Global DNA Hydroxymethylation Quantification Technologies Published 05/31/2012 |
|||
NEW YORK, May 31 - Epigentek Group Inc. announced today that the United States Patent and Trademark Office (USPTO) has awarded a Notice of Allowance to the company for a patent to cover novel methods of rapid quantification of global DNA hydroxymethylation. Several of Epigentek's key products, including the popular MethylFlash Hydroxmethylated DNA Quantification Kit, utilizes technology based on this patent.
It is believed that DNA hydroxymethylation or 5-hydroxymethylcytosine (5-hmC) formation in the genome DNA plays an important role in switching genes on and off. Alteration of methylation/hydroxymethylation has been proposed as a useful molecular marker in multiple biological processes including cancer. Thus, the quantification of global methylation/hydroxymethylation in cancer could provide very useful information for detection and analysis of such a disease. This key patent award further solidifies Epigentek’s intellectual property and product portfolio, particularly in the realm of global DNA methylation/hydroxymethylation detection technologies. This new technology can be used for rapidly and accurately identifying hydroxymethylated DNA or 5-hmC in a high throughput format, suitable from any species including mammals, plants, fungi, bacteria, and viruses in a variety of forms including cultured cells, fresh and frozen tissues, paraffin-embedded tissues, plasma/serum samples, and body fluid samples. About Epigentek Group Inc. Epigentek is a leading biotechnology company that focuses on developing and providing innovative technologies and products as a complete and systematic solution for epigenetic related research and drug discovery. Visit our informative website at www.epigentek.com |
|||
Terms & Conditions | Privacy Policy | Site Map |
| Copyright © EpigenTek Group Inc. All rights reserved. |